Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Baxter Announces Long-Term Partnership in Brazil

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
Company to expand access to recombinant FVIII hemophilia treatment.

Baxter International Inc. has announced an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A.

Hemophilia A is a genetic condition in which the body does not produce enough clotting protein factor VIII.

It is estimated that more than 10,000 people in Brazil are living with hemophilia A, and the vast majority are treated with plasma-derived FVIII therapy.

Baxter recently highlighted the importance of developing innovative business models, including public and private partnerships, aimed at improving the quality of and access to care in both developed and emerging markets.

"Our unique collaboration with Hemobrás is a demonstration of Baxter's leadership in hemophilia, reflects our expertise and commitment to the community, and positions us as an attractive partner that can make a significant impact on expanding access to quality care to patients around the world," said Robert L. Parkinson, Jr., Baxter chairman and chief executive officer.

Parkinson continued, "This agreement establishes Baxter as the provider of choice in Brazil and builds upon Baxter's long-standing presence in this large and growing market."

Through this innovative partnership, Baxter will be the exclusive provider of Brazil's recombinant FVIII treatment over the next 10 years while the companies work together on the technology transfer to support development of local manufacturing capacity by Hemobrás.

Baxter will receive cash payments for product it supplies to Hemobrás and, following completion of the technology transfer, royalties on recombinant FVIII produced by Hemobrás. The company expects peak annual sales to exceed $200 million.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Baxter to Acquire Oncaspar® Portfolio for Leukemia
New portfolio strengthens leadership in rare and orphan diseases for Baxter, expected to become Baxalta by mid-2015.
Saturday, May 16, 2015
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Agreement includes all assets related to the platform, including vaccines for H5N1, H1N1 and seasonal influenza.
Thursday, December 18, 2014
Baxter to Form New Global Innovation and R&D Center
Company plans to form new center near Boston for its biopharmaceuticals business.
Friday, October 10, 2014
Baxter and Merrimack Enter into Exclusive Ex-U.S. Licensing Agreement
Baxter gains exclusive commercialization rights for all potential indications of MM-398 in all other geographies outside Taiwan.
Friday, September 26, 2014
Baxter Acquires AesRx, LLC
Program carries potential to address significant unmet patient need.
Thursday, July 10, 2014
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's
Phase III clinical study of immunoglobulin (IG) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer’s disease.
Thursday, May 09, 2013
Baxter Announces FDA Approval of ADVATE 4000 IU Dosage Strength
New size expands convenience options for hemophilia A patients.
Wednesday, July 18, 2012
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!